ERBB2 and cancer: TICs are observed in multiple subtypes of breast cancer [4,5], including Her2+ cancers and triple negative breast cancer (TNBC), an aggressive subtype of breast cancer characterized by the loss of estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu [6].